Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma

Med Clin (Barc). 2024 Apr 12;162(7):358-359. doi: 10.1016/j.medcli.2023.11.003. Epub 2023 Dec 2.

[Article in English, Spanish]

Authors

Thais Lizondo López¹, Iria Carro Méndez², Esther Carcelero San Martín²

Affiliations

¹ Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain. Electronic address: tlizondo@clinic.cat.
² Pharmacy Service, Division of Medicines, Hospital Clínic Barcelona, Barcelona, Spain.

PMID: 38044186
DOI: 10.1016/j.medcli.2023.11.003

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized*
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy
Myocarditis* / chemically induced
Myocarditis* / diagnosis
Myositis* / chemically induced

Substances

tremelimumab
durvalumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized